REGENXBIO at SfN 2026
Nov 14–18, 2026 Washington, DC ~21k attendees Website
REGENXBIO brings 2 presentations to SfN 2026 in Washington. Its presentations at this meeting centre on AAV gene delivery for neuromuscular disease and delivery to the central nervous system while limiting peripheral tissue transduction. One study tests whether an AAV-expressed microdystrophin with an extended C-terminal domain can rescue neuromuscular junction deficits in a mouse model of Duchenne muscular dystrophy.
| Organization | SfN 2026 Attendance |
|---|---|
REGENXBIO Rockville, MD | |
Clinical-stage biotechnology company developing AAV gene therapies, based in Rockville, Maryland. | Poster Tue Nov 17 1–5pm |
Instantly find 20 buyers from REGENXBIO
Get a list of who you should contact, their contact info, and what to say.
Totally free and instant, no sign up necessary!
Not affiliated with the Society for Neuroscience. Organization details are derived from SfN’s published exhibitor list, its Neuroscience Meeting Planner and each organization’s own website. Submit a correction